GCM
ALNY icon

Genus Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Genus Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,990
Closed -$1.41M – 191
2024
Q4 		$1.41M Buy
+5,990
New +$1.58M 0.19% 117

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Genus Capital Management's ALNY Position: Q1 2026 in Review

Genus Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 5,255 shares — an estimated $2.09M sold.

Genus Capital Management first reported a position in ALNY in Q1 2025 and held it in 4 quarters. The position peaked at $3.77M in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Genus Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Genus Capital Management sold 5,255 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $2.09M.
  • Genus Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • Genus Capital Management's Alnylam Pharmaceuticals position peaked at $3.77M in Q3 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Genus Capital Management's 13F filing for Q1 2026, filed 4 May 2026.